Zanubrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase I/II study in patients with various B-cell malignancies. Zanubrutinib was well tolerated and demonstrated activity in patients with relapsed/refractory mantle cell lymphoma.